TD Cowen Initiates Coverage On Dyne Therapeutics with Buy Rating

Benzinga Newsdesk www.benzinga.com Neutral 52.1%

Neg 0% Neu 52.1% Pos 0%

TD Cowen analyst Joseph Thome initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Buy rating.

Comments

No comments yet. Be the first!